ReviewCureus2018
A Review of the Mechanism of Antagonism of N-methyl-D-aspartate Receptor by Ketamine in Treatment-resistant Depression.
Review in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.CNS drugs · 2023Pooled it
- Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.Frontiers in pharmacology · 2022Pooled it
- Suspected cumulative neuro-ophthalmic toxicity after chronic oral exposure to the veterinary anesthetic tiletamine: a case report.Frontiers in veterinary science · 2026Article
- Pathogenesis of HIV-associated depression: contributing factors and underlying mechanisms.Frontiers in psychiatry · 2025Review
- Evaluation of New Approaches to Depression Treatment Using an Animal Model of Pharmacoresistant Depression.International journal of molecular sciences · 2024Article
- Case report: Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion.Frontiers in pain research (Lausanne, Switzerland) · 2023Article
- Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications.Molecular psychiatry · 2022Review
- Larval Zebrafish as a Model for Mechanistic Discovery in Mental Health.Frontiers in molecular neuroscience · 2022Review
- Evaluation of Inflammatory Response System (IRS) and Compensatory Immune Response System (CIRS) in Adolescent Major Depression.Journal of inflammation research · 2022Article
- Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review.Cureus · 2021Review
- Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?Frontiers in neuroscience · 2021Review
- Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report.Therapeutic advances in psychopharmacology · 2021Article
- Neuronal Plasticity: Neuronal Organization is Associated with Neurological Disorders.Journal of molecular neuroscience : MN · 2020Review
- Serum Metabolic Profiling Reveals the Antidepressive Effects of the Total Iridoids ofFrontiers in pharmacology · 2020Article
- Direct Medial Entorhinal Cortex Input to Hippocampal CA3 Is Crucial for eEF2K Inhibitor-Induced Neuronal Oscillations in the Mouse Hippocampus.Frontiers in cellular neuroscience · 2020Article
- Intranasal Esketamine (SpravatoP & T : a peer-reviewed journal for formulary management · 2019Article
- Synaptic Plasticity Changes: Hallmark for Neurological and Psychiatric Disorders.Neural plasticity · 2018Article
- Cognition Enhancing Potential of Aqueous Leaf Extract ofJournal of evidence-based integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biochemical processes involved in depression go beyond serotonin, norepinephrine, and dopamine. The N-methyl-D-aspartate (NMDA) receptor has a major role in the neurophysiology of depression. Ketamine, one of the prototypical NMDA antagonists, works rapidly in controlling depressive symptoms, including acutely suicidal behavior, by just a single injection. Ketamine may rapidly increase the glutamate levels and lead to structural neuronal changes. Increased neuronal dendritic growth may contribute to synaptogenesis and an increase in brain-derived neurotrophic factor (BDNF). Activation of the mechanistic target of rapamycin (mTOR), as well as increased levels of BDNF, may increase long-term potentiation and result in an improvement in the symptoms of depression. The mechanisms of ketamine's proposed effect as an off-label treatment for resistant depression are outlined in this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.